ROBO1, together with multiple ICMs, including CTLA-4, PD-1, and programmed death-ligand 1 (PD-L1), have been considered potential target antigens for effective HCC radioimmunotherapy [91]. This evidence concerns the gene PDCD1 and hepatocellular carcinoma.